Skip to content
Late-StageResearch compoundModerate evidence

Meclofenoxate

Older-type nootropic for age-related memory complaints; modest improvement in trials, sold as a medicine in some countries.

NootropicCholinergicCholinergicNeuroprotectionAcetylcholinenoo.affects.neuroprotectionnoo.affects.memory

Pharmacology

ClassCholinergic · Neuroprotection
Primary targetAcetylcholine precursor (via DMAE) and lipofuscin clearance
Targets4 receptor targets
Half-lifeShort: meclofenoxate is rapidly hydrolyzed to DMAE and 4-chlorophenoxyacetic acid; a precise human half-life is not well documented
OnsetOral, dosed morning to early afternoon with food; cognitive effects usually build over days to weeks
EvidenceModerate evidence
Affected systemsAcetylcholinenoo.affects.neuroprotectionnoo.affects.memory

Contents

DETAILED OVERVIEW

What is Meclofenoxate?

Meclofenoxate (also called centrophenoxine) is an older-type nootropic, meaning a substance meant to support thinking, that has been studied for memory complaints linked to brain aging. In France, Japan and other countries it has been sold as a medicine under the name Lucidril, but in the United States and several EU countries it has no medicine approval. It is not on the anti-doping list.

In the body it is thought to break down into a substance called DMAE, a building block of acetylcholine, a brain messenger. It is also an antioxidant and reduces the age pigment that builds up in nerve cells. In controlled trials in elderly patients with dementia or organic brain symptoms it gave a modest but measurable improvement in memory and was generally well tolerated. It can cause insomnia, restlessness, headache or dizziness. It should be avoided in pregnancy and breastfeeding because its safety is not established; in people prone to seizures it could in theory make things worse.

Mechanism

Releases DMAE; antioxidant; helps clear age pigment

Evidence

Double-blind trials in elderly/demented patients (modest effect)

Legal status

Medicine in some countries (Lucidril), supplement elsewhere

Receptor profile

  • Acetylcholine (via DMAE/choline)Moderate
  • Lipofuscin (age pigment) clearanceModerate
  • Phosphatidylcholine / membrane structureModerate
  • Antioxidant enzymes (ROS scavenging)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Insomnia, restlessness or headache, especially with late or high dosing
  • Dizziness or nausea in some individuals
  • Mild muscle tension or neck stiffness attributed to the DMAE component
  • Irritability or overstimulation if dosed close to sleep
  • Generally reported as well tolerated in clinical studies

Contraindications · 4

  • Pregnancy and breastfeeding: DMAE derivatives should be avoided, safety not established
  • Epilepsy or seizure susceptibility: cholinergic enhancement may theoretically lower the seizure threshold
  • Severe agitation, manic states or uncontrolled hypertension
  • Avoid late-evening dosing due to the risk of sleep disruption

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Meclofenoxate is an older, cholinergic-type nootropic mainly studied for easing age-related memory problems and cognitive decline. Double-blind trials showed a modest improvement in memory and cognition in elderly patients with organic brain syndrome, likely by boosting cholinergic brain signaling and reducing the buildup of a cellular waste pigment (lipofuscin) linked to aging. It also has antioxidant properties and was generally well tolerated in studies, though its effect is best described as modest rather than dramatic.

Telegram

Have a question about Meclofenoxate?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC12H16ClNO3
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.